EpicentRx is dedicated to developing innovative therapies aimed at addressing inflammatory diseases and unmet medical needs in supportive care. Central to their approach is the PRETECT platform, which features RRx-001, a first-in-class small molecule designed to inhibit the NLRP3 inflammasome. This mechanism is crucial as chronic inflammation can lead to tissue damage and various disorders, including cancer. RRx-001 has received Fast Track designation for treating severe oral mucositis in head and neck cancer, highlighting its potential in supportive care. Additionally, the company is exploring RRx-001's applications in neurodegenerative diseases, with ongoing studies supported by grants from organizations like the Michael J. Fox Foundation and FightMND.

Another key technology from EpicentRx is the AdAPT platform, which includes AdAPT-001, an immune checkpoint-stimulating immunotherapy. This therapy is designed to enhance the immune response against cancer by neutralizing the TGFβ protein, which typically silences T-cell activity within tumors. By producing a proprietary TGFβ "trap," AdAPT-001 aims to sustain immune activation against cancer cells, either alone or in combination with other immune checkpoint inhibitors. Together, these platforms represent EpicentRx's commitment to advancing treatment options that not only target diseases but also improve patient quality of life during therapy.

United States

EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” - ease of treatment, ease of side effects, and ease of symptoms during the treatment of a range of diseases including lung cancer, and head and neck cancer, and different inflammatory disorders for which the company has received several grants and orphan designations.

The lead device is called the eLOOP and the lead therapies are the direct NLRP3 inhibitor, nibrozetone (RRx-001), and the TGF-β trap-enhanced oncolytic adenovirus, AdAPT-001, in Phase 3, and Phase 2 clinical trials, respectively. 

EpicentRx

Company Details